MX2023014709A - Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o. - Google Patents

Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o.

Info

Publication number
MX2023014709A
MX2023014709A MX2023014709A MX2023014709A MX2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A
Authority
MX
Mexico
Prior art keywords
norepinephrine reuptake
sleep apnea
reuptake inhibitors
treating sleep
optionally
Prior art date
Application number
MX2023014709A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence G Miller
Ronald Farkas
Luigi Taranto-Montemurro
David P White
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of MX2023014709A publication Critical patent/MX2023014709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023014709A 2021-06-17 2022-06-17 Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o. MX2023014709A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211673P 2021-06-17 2021-06-17
US202263319035P 2022-03-11 2022-03-11
PCT/US2022/033987 WO2022266440A1 (en) 2021-06-17 2022-06-17 Norepinephrine reuptake inhibitors for treating sleep apnea

Publications (1)

Publication Number Publication Date
MX2023014709A true MX2023014709A (es) 2024-01-15

Family

ID=82608262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014709A MX2023014709A (es) 2021-06-17 2022-06-17 Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o.

Country Status (10)

Country Link
US (1) US20240277719A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355333A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024523876A (cg-RX-API-DMAC7.html)
KR (1) KR20240021920A (cg-RX-API-DMAC7.html)
AU (1) AU2022294086A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026158A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221848A1 (cg-RX-API-DMAC7.html)
IL (1) IL309251A (cg-RX-API-DMAC7.html)
MX (1) MX2023014709A (cg-RX-API-DMAC7.html)
WO (1) WO2022266440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN119185558A (zh) * 2017-04-28 2024-12-27 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh) * 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
ES3049086T3 (en) * 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
KR20240021920A (ko) 2024-02-19
EP4355333A1 (en) 2024-04-24
US20240277719A1 (en) 2024-08-22
WO2022266440A1 (en) 2022-12-22
CA3221848A1 (en) 2022-12-22
BR112023026158A2 (pt) 2024-03-05
JP2024523876A (ja) 2024-07-02
IL309251A (en) 2024-02-01
AU2022294086A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
MX2024001713A (es) Metodos y composiciones para tratar la apnea del sue?o.
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
ZA202212095B (en) Il4i1 inhibitors and methods of use
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
EA202192202A1 (ru) Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
CA3265870A1 (en) Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses
MX2023014704A (es) Inhibidores de proteasa para el tratamiento de infecciones por coronavirus.
CR10253A (es) "inhibidores de pai-1 para tratamiento de afecciones musculares"
MX2021005944A (es) Inhibidores de rip1.
MX2022012001A (es) Tratamiento preventivo de la migra?a.